Catherine C. Coombs, MD, UNC School of Medicine
Advertisement
Articles by Catherine C. Coombs, MD, UNC School of Medicine
Catherine Callaghan Coombs, MD, discusses the efficacy results of the ongoing phase 1/2 BRUIN study with pirtobrutinib in chronic lymphocytic leukemia.
Advertisement
Latest Updated Articles
Therapeutic Sequencing in Relapsed/Refractory CLLJanuary 8th 2021
Allogeneic Transplantation for CLLJanuary 8th 2021
Frontline CLL Treatment: Addressing Unmet NeedsJanuary 8th 2021
Selecting Frontline Therapy to Treat CLLJanuary 8th 2021
Frontline CLL Treatment With Fixed-Duration RegimensJanuary 8th 2021
Minimal Residual Disease in CLLJanuary 8th 2021
Advertisement
Advertisement
Trending on OncLive
1
FDA Approves Dostarlimab for dMMR/MSI-H Locally Advanced Rectal Cancer
2
FDA Clears TumorSight Risk, an MRI-Derived AI Recurrence Tool for HR+, HER2– Breast Cancer
3
Dr Cercek on the FDA Approval of Dostarlimab for dMMR/MSI-H Locally Advanced Rectal Cancer
4
Vilamakitug Meets OS Threshold in Phase 1/2 Refractory mCRC Trial
5